GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative to daily pills and addressing the needs of key populations.

A newly approved HIV prevention drug, lenacapavir, is set to be introduced in at least nine countries in early 2026, and Rwanda could be among the first to deploy it, government and World Health ...

As Professor of Infectious Diseases and Microbiology Paul Griffin explains in a recent piece for The Conversation, Stratus is ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

U.N. health officials have estimated that more than 14 million children did not receive a single vaccine last year.

An estimated 14.3 million children globally remain unvaccinated and vulnerable to vaccine-preventable illnesses – meaning ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

The World Health Organization has formally recognized the pivotal role of a number of heads of state and government in securing the adoption of the WHO Pandemic Agreement by the Seventy-eighth World ...

The Global Network for Academic Public Health (GNAPH), for which ASPPH proudly serves as Secretariat, has formalized a ...

WHO still seeking COVID-19 origin, says all scenarios ‘remain on the table’ The World Health Organization's probe into the cause of COVID-19 has not resulted in a definitive reason, with its ...